Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation
Corey Cutler(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Vincent T. Ho(Dana-Farber Cancer Institute), Paul G. Richardson(Harvard University), Erica Linden(Dana-Farber Cancer Institute), Haesook T. Kim(Dana-Farber Cancer Institute), Shelly Carter(European Society for Blood and Marrow Transplantation), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Sung Won Choi(University of Michigan), Ruth Ebert(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mary M. Horowitz(Medical College of Wisconsin), Kristen E. Stevenson(Dana-Farber Cancer Institute), Carolyn Revta(Dana-Farber Cancer Institute), Diane Warren(Dana-Farber Cancer Institute), John Koreth(Otsuka (Japan))
Cited by 155
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k